Repositioning Candidate Details
| Candidate ID: | R0324 |
| Source ID: | DB00884 |
| Source Type: | approved; investigational |
| Compound Type: | small molecule |
| Compound Name: | Risedronic acid |
| Synonyms: | Risedronate; Risedronic acid |
| Molecular Formula: | C7H11NO7P2 |
| SMILES: | OC(CC1=CN=CC=C1)(P(O)(O)=O)P(O)(O)=O |
| Structure: |
|
| DrugBank Description: | Risedronic acid is a third generation bisphosphonate that is used for the treatment of some forms of osteoperosis and Paget's disease. It functions by preventing resorption of bone. |
| CAS Number: | 105462-24-6 |
| Molecular Weight: | 283.1123 |
| DrugBank Indication: | Risedronic acid is indicated for the treatment of osteoperosis in men, treatment of Paget's disease, treatment and prevention of osteoperosis in postmenopausal women, and treatment and prevention of glucocorticoid-induced osteoperosis. |
| DrugBank Pharmacology: | Risedronate is a pyridine-based bisphosphonate that inhibits bone resorption caused by osteoclasts. |
| DrugBank MoA: | Risedronatic acid binds to bone hydroxyapatite. Bone resorption causes local acidification, releasing risedronic acid which is that taken into osteoclasts by fluid-phase endocytosis. Endocytic vesicles are acidified, releasing risedronic acid to the cytosol of osteoclasts where they induce apoptosis through inhbition of farnesyl pyrophosphate synthase. Inhibition of osteoclasts results in decreased bone resorption. |
| Targets: | Farnesyl pyrophosphate synthase inhibitor; Hydroxylapatite antagonist |
| Inclusion Criteria: | Therapeutic strategy associated |
